BioVersys gets €20m EIB loan to develop novel antibioticsLatest NewsSwiss BioVersys has received €20mfrom the European Investment Bank to push the development of new drugs against life-threatening nosocomial infections. Read more 14 April 2021 https://european-biotechnology.com/wp-content/uploads/2024/04/acinetobacter-spp-cdc-medical-illustration.png 285 369 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2021-04-14 08:44:002021-04-14 08:44:00BioVersys gets €20m EIB loan to develop novel antibiotics
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractLatest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. Read more 13 April 2021 https://european-biotechnology.com/wp-content/uploads/2024/04/1024px-Psoriasisplaque.jpeg 797 1024 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2021-04-13 11:33:002021-04-13 11:33:00C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractLatest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. Read more 13 April 2021 https://european-biotechnology.com/wp-content/uploads/2024/04/1024px-Psoriasisplaque.jpeg 797 1024 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2021-04-13 11:33:002021-04-13 11:33:00C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractLatest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. Read more 13 April 2021 https://european-biotechnology.com/wp-content/uploads/2024/04/1024px-Psoriasisplaque.jpeg 797 1024 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2021-04-13 11:33:002021-04-13 11:33:00C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractLatest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. Read more 13 April 2021 https://european-biotechnology.com/wp-content/uploads/2024/04/1024px-Psoriasisplaque.jpeg 797 1024 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2021-04-13 11:33:002021-04-13 11:33:00C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractLatest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. Read more 13 April 2021 https://european-biotechnology.com/wp-content/uploads/2024/04/1024px-Psoriasisplaque.jpeg 797 1024 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2021-04-13 11:33:002021-04-13 11:33:00C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractLatest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. Read more 13 April 2021 https://european-biotechnology.com/wp-content/uploads/2024/04/1024px-Psoriasisplaque.jpeg 797 1024 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2021-04-13 11:33:002021-04-13 11:33:00C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractLatest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. Read more 13 April 2021 https://european-biotechnology.com/wp-content/uploads/2024/04/1024px-Psoriasisplaque.jpeg 797 1024 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2021-04-13 11:33:002021-04-13 11:33:00C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractLatest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. Read more 13 April 2021 https://european-biotechnology.com/wp-content/uploads/2024/04/1024px-Psoriasisplaque.jpeg 797 1024 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2021-04-13 11:33:002021-04-13 11:33:00C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractLatest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. Read more 13 April 2021 https://european-biotechnology.com/wp-content/uploads/2024/04/1024px-Psoriasisplaque.jpeg 797 1024 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2021-04-13 11:33:002021-04-13 11:33:00C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
BioVersys gets €20m EIB loan to develop novel antibiotics
Latest NewsSwiss BioVersys has received €20mfrom the European Investment Bank to push the development of new drugs against life-threatening nosocomial infections.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.